CLOs on the Move

Patheon

www.patheon.com

 
At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. With a reputation for scientific and technical excellence, combined with a passion for delivering quality products on time, every time, our approximately 8,700 employees across North America, Europe, Latin America and Australia have enabled Patheon to achieve industry-leading growth. When you ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.patheon.com
  • 4721 Emperor Blvd Ste 200
    Durham, NC USA 27703
  • Phone: 919.226.3200

Executives

Name Title Contact Details
Eric Sherbet
General Counsel Profile

Similar Companies

SCOLR Pharma Inc

SCOLR Pharma Inc is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VoCare

The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...

Bioheart

Founded in 1999, Bioheart, Inc. is committed to the development of effective cell technologies to treat cardiovascular diseases.

Mccrone Group Inc

Mccrone Group Inc is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Oncopeptides

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.